Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Disufenton (Primary)
- Indications Glioma
- Focus Adverse reactions
- Sponsors Oblato
- 22 Sep 2017 Planned End Date changed from 1 jun 2017 to 1 Nov 2018.
- 22 Sep 2017 Planned primary completion date changed from 1 jun 2017 to 1 Sep 2018.
- 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.